Evidence map›Paper›PMID 19356249›Full record

ArticleBMC cancer2009

Immunostaining with D2-40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer.

Anna V Britto, André A Schenka, Natália G Moraes-Schenka, Marcelo Alvarenga, Júlia Y Shinzato, José Vassallo, Laura S Ward

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anna V BrittoMolecular Genetics of Cancer Laboratory, Department of Internal Medicine, School of Medical Sciences, State University of Campinas, São Paulo, Brazil. avbritto@yahoo.com
André A Schenka
Natália G Moraes-Schenka
Marcelo Alvarenga
Júlia Y Shinzato
José Vassallo
Laura S Ward
Universidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSentinel lymph node (SLN) biopsy is a widely used diagnostic procedure in the management of early breast cancer. When SLN is free of metastasis, complete axillary dissection may be skipped for staging in clinically N0 patients, allowing a more conservative procedure. Histological tumor features that could reliably predict SLN status have not yet been established. Since the degree of tumor lymphangiogenesis and vascularization may theoretically be related to the risk of lymph node metastasis, we sought to evaluate the relationship between lymph vessel invasion (LVI), lymphatic microvascular density (LVD), microvascular density (MVD) and VEGF-A expression, with SLN status and other known adverse clinical risk factors.

methodsProtein expression of D2-40, CD34, and VEGF-A was assessed by immunohistochemistry on paraffin-embedded sections of primary breast cancer specimens from 92 patients submitted to SLN investigation. The presence of LVI, the highest number of micro vessels stained for D2-40 and CD34, and the protein expression of VEGF-A were compared to SLN status, clinicopathological features and risk groups.

resultsLVI was detected in higher ratios by immunostaining with D2-40 (p < 0.0001), what would have changed the risk category from low to intermediate in four cases (4.3%). There was no association between LVI and other angiogenic parameters determined by immunohistochemistry with SLN macrometastases, clinical features or risk categories.

conclusionAssessment of LVI in breast carcinoma may be significantly increased by immunostaining with D2-40, but the clinical relevance of altering the risk category using this parameter may not be advocated according to our results, neither can the use of LVI and LVD as predictors of SLN macrometastasis in early breast cancer.

Indexed as

LymphangiogenesisAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD34Biomarkers, TumorBreast NeoplasmsFemaleHumansImmunohistochemistryLogistic ModelsLymphatic MetastasisMembrane GlycoproteinsMiddle AgedNeovascularization, PathologicAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD34Biomarkers, TumorMembrane Glycoproteinsmonoclonal antibody D2-40PDPN protein, humanPodoplaninVascular Endothelial Growth Factor A

Identifiers

PMID19356249
PMCPMC2674880
OpenAlexW2162993810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.